Welcome to our dedicated page for Mink Therapeutics news (Ticker: INKT), a resource for investors and traders seeking the latest updates and insights on Mink Therapeutics stock.
MiNK Therapeutics, Inc. (INKT) is a clinical-stage biopharmaceutical company pioneering allogeneic iNKT cell therapies for cancer and immune-mediated diseases. This page provides investors and industry observers with timely updates on material developments, including clinical trial progress, regulatory milestones, and strategic partnerships.
Access verified press releases and news articles covering MiNK Therapeutics' innovative pipeline, manufacturing advancements, and collaborative research initiatives. Content spans earnings announcements, trial data disclosures, executive leadership updates, and scientific presentations relevant to the company’s position in the immunotherapy sector.
Bookmark this page for streamlined tracking of INKT’s progress in developing off-the-shelf cellular therapies. Check regularly for authoritative updates that inform analysis of the company’s scientific and commercial trajectory.
MiNK Therapeutics reported its Q2 2022 financial results, highlighting ongoing advancements in its clinical programs, particularly AgenT-797 for cancer and viral ARDS. The company completed internal cGMP production capable of treating over 700,000 patients annually. Clinical data updates for AgenT-797 and a novel stromal-CAR-iNKT program are anticipated in the second half of 2022. Financially, MiNK ended Q2 with $29.8 million in cash and reported a net loss of $6.1 million, slightly improving from the previous year. The leadership team has also been expanded, notably appointing Dr. Joy Zhou as VP of CMC.
MiNK Therapeutics, a clinical-stage biopharmaceutical company specializing in allogeneic iNKT cell therapies for cancer and immune-mediated diseases, will attend the BTIG 2022 Biotechnology Conference. The company will participate virtually and conduct one-on-one meetings with investors on August 8th and 9th. MiNK is advancing both native and engineered iNKT programs, focusing on scalable and reproducible manufacturing for off-the-shelf delivery. For more details, visit their website at minktherapeutics.com.
MiNK Therapeutics, a clinical-stage biopharmaceutical company, will announce its Q2 2022 financial results prior to the market opening on August 9, 2022. A conference call is scheduled for 11:00 a.m. ET on the same day to discuss the results and provide corporate updates. MiNK specializes in developing allogeneic invariant natural killer T (iNKT) cell therapies aimed at treating cancer and immune-mediated diseases, with a focus on scalable and reproducible manufacturing.
MiNK Therapeutics, a biopharmaceutical company focusing on allogeneic invariant natural killer T (iNKT) cell therapies, announced its virtual Annual Meeting of Shareholders set for June 8, 2022, at 5:00 PM ET. Shareholders can join via a dedicated website using a control number from proxy materials, while guests can listen without a control number. The company aims to advance its pipeline of iNKT programs targeting cancer and immune-mediated diseases, with scalable and reproducible manufacturing processes.
MiNK Therapeutics announced its Q1 2022 results, reporting a cash balance of $34.7 million and a projected 2022 cash burn of $16.8 million. The company is progressing well with its clinical programs, including agenT-797 studies for solid tumors and multiple myeloma, aiming for data readouts in 2H 2022. They launched an in-house GMP manufacturing process targeting 10,000 doses/year and advanced their pipeline with IND enabling studies for BCMA-CAR-iNKT.
However, net losses for Q1 were $7.8 million, up from $3.8 million in Q1 2021, driven by increased clinical activities.
MiNK Therapeutics, a clinical-stage biopharmaceutical company focused on iNKT cell therapies for cancer and immune-mediated diseases, will announce its Q1 2022 financial results and business update on May 10, 2022, before market opens. The disclosure will be made via press release and available on the company's investor website. MiNK is advancing a pipeline of native and next-generation engineered iNKT therapies, aiming for scalable off-the-shelf delivery.
MiNK Therapeutics (NASDAQ: INKT) is advancing its allogeneic invariant natural killer T (iNKT) cell therapies, particularly AgenT-797, in ongoing clinical trials for solid tumors and COVID-19 related ARDS, showing a remarkable 75% survival rate in treated patients. No lymphodepletion or serious side effects such as cytokine release syndrome have been reported. The company completed a $46 million IPO and recorded a cash burn of approximately $13 million in 2021, with a cash balance of $39 million as of year-end. MiNK plans to manufacture over 10,000 doses of iNKT cells annually to support its clinical programs.
MiNK Therapeutics, a clinical-stage biopharmaceutical company, will announce its fourth quarter and full year 2021 financial results and business update on March 18, 2022. The company specializes in developing allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases. The financial report will be accessible via a press release and the investor section of the company's website. MiNK's pipeline includes native and engineered iNKT programs aimed at scalable manufacturing and off-the-shelf delivery.
MiNK Therapeutics has initiated a Phase 1 clinical trial for AgenT-797, targeting patients with solid tumor cancers. The therapy can be dosed up to 1 billion cells without lymphodepletion, showing no signs of cytokine release syndrome or neurotoxicity. Clinical trials are also being conducted for multiple myeloma and viral ARDS. Preliminary results indicate a favorable safety profile and promising early clinical activity, especially when combined with approved anti-PD-1 checkpoint inhibitors. The company is focused on developing allogeneic iNKT cell therapies for cancer treatment.
MiNK Therapeutics announced that Dr. Jennifer Buell, President and CEO, will participate in a fireside chat at the B. Riley Securities Virtual Oncology Investor Conference on January 27, 2022, at 12:00 PM ET. The event will discuss the company's advancements in iNKT cell therapies aimed at treating cancer and immune-mediated diseases. Investors can access the live presentation and a replay through MiNK's website after the event.
MiNK is focused on developing scalable iNKT cell therapies, enhancing treatment options in oncology.
FAQ
What is the current stock price of Mink Therapeutics (INKT)?
What is the market cap of Mink Therapeutics (INKT)?
